Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report)’s stock price was up 5.3% during mid-day trading on Tuesday. The company traded as high as $110.26 and last traded at $110.6320. 831,811 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 1,788,709 shares. The stock had previously closed at $105.04.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Canaccord Genuity Group reduced their price objective on Twist Bioscience from $205.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, November 13th. Leerink Partners dropped their target price on shares of Twist Bioscience from $190.00 to $175.00 and set an “outperform” rating for the company in a research report on Friday, November 13th. Guggenheim raised their price target on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Robert W. Baird reduced their price target on shares of Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, November 13th. Finally, BWS Financial reiterated a “sell” rating and set a $45.00 price objective on shares of Twist Bioscience in a research note on Friday, September 18th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $133.92.
View Our Latest Report on TWST
Twist Bioscience Price Performance
The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The company has a market cap of $7.00 billion, a PE ratio of -53.41 and a beta of 2.25. The company has a 50-day moving average price of $149.33 and a two-hundred day moving average price of $94.12.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. The business had revenue of $126.64 million for the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The firm’s revenue was up 26.7% on a year-over-year basis. Sell-side analysts expect that Twist Bioscience Corporation will post -1.42 earnings per share for the current fiscal year.
Insider Activity at Twist Bioscience
In other news, CFO Adam Laponis sold 2,462 shares of the business’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $156.30, for a total transaction of $384,810.60. Following the transaction, the chief financial officer directly owned 98,114 shares of the company’s stock, valued at approximately $15,335,218.20. The trade was a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 1,007 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total transaction of $136,347.80. Following the completion of the transaction, the senior vice president owned 105,625 shares of the company’s stock, valued at $14,301,625. This trade represents a 0.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 495,279 shares of company stock valued at $80,489,387. 3.08% of the stock is currently owned by corporate insiders.
Institutional Trading of Twist Bioscience
Several large investors have recently modified their holdings of TWST. Western Wealth Management LLC acquired a new position in shares of Twist Bioscience in the first quarter worth about $31,000. Root Financial Partners LLC acquired a new stake in Twist Bioscience during the 3rd quarter valued at approximately $33,000. Steward Partners Investment Advisory LLC grew its stake in Twist Bioscience by 99.0% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 203 shares of the company’s stock valued at $39,000 after purchasing an additional 101 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after purchasing an additional 453 shares during the last quarter. Finally, Fifth Third Bancorp purchased a new stake in Twist Bioscience during the 1st quarter worth approximately $54,000.
Twist Bioscience Company Profile
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
See Also
- Five stocks we like better than Twist Bioscience
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
